biphozyl so.hmf.hmd 22mmol/l
baxter holding b.v., the netherlands kobaltweg 49, 3542ce utrecht - magnesium chloride hexahydrate; sodium chloride; sodium bicarbonate; potassium chloride; disodium phosphate dihydrate - so.hmf.hmd (ΔΙΑΛΥΜΑ ΑΙΜΟΔΙΗΘΗΣΗΣ, ΑΙΜΟΔΙΑΠΙΔΥΣΗΣ (ΑΙΜΟΚΑΘΑΡΣΗΣ)) - 22mmol/l - magnesium chloride hexahydrate 3,05g; sodium chloride 7,01g; sodium bicarbonate 2,12g; potassium chloride 0,314g; disodium phosphate dihydrate 0,187g - hemofiltrates
regiocit haemof.sol (5,29+5,03)g/l
baxter holding b.v., the netherlands kobaltweg 49, 3542ce utrecht - sodium citrate; sodium chloride - haemof.sol (ΔΙΑΛΥΜΑ ΑΙΜΟΔΙΗΘΗΣΗΣ) - (5,29+5,03)g/l - sodium citrate 5,29g; sodium chloride 5,03g - hemofiltrates
celdoxome pegylated liposomal
yes pharmaceutical development services gmbh - υδροχλωρική δοξορουβικίνη - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - Αντινεοπλασματικοί παράγοντες - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).
metronidazole 0.5% solution for infusion
baxter (hellas) epe (0000008332) 47, marinou antypa & anafis str, n. herakleio-attiki, 141 21 - metronidazole - solution for infusion - 0.5% - metronidazole (0000443481) 0,5g - metronidazole
subcuvia 160mg/ml inj.sol
baxter ag, vienna, austria - immunoglobulins, normal human, for extravascular adm. - ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ - 160mg/ml - ΠΡΟΙΟΝ ΑΙΜΑΤΟΣ (ΠΑ)
sodium chloride 0.9%/baxter 0,9% inj.so.inf
baxter hellas ΕΠΕ - sodium chloride - ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ ΓΙΑ ΕΝΔΟΦΛΕΒΙΑ ΕΓΧΥΣΗ - 0,9% - ΔΙΑΛΥΜΑ ΕΝΕΣΙΜΟ ΜΕΓΑΛΟΥ ΟΓΚΟΥ ( >50 ml )
ringer lactate/baxter inj.so.inf inj.so.inf
baxter hellas ΕΠΕ - electrolytes - ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ ΓΙΑ ΕΝΔΟΦΛΕΒΙΑ ΕΓΧΥΣΗ - inj.so.inf - ΔΙΑΛΥΜΑ ΕΝΕΣΙΜΟ ΜΕΓΑΛΟΥ ΟΓΚΟΥ ( >50 ml )
ringer's solution/baxter (0.86+0.03+0.033)% inj.so.inf
baxter hellas ΕΠΕ - electrolytes - ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ ΓΙΑ ΕΝΔΟΦΛΕΒΙΑ ΕΓΧΥΣΗ - (0.86+0.03+0.033)% - ΔΙΑΛΥΜΑ ΕΝΕΣΙΜΟ ΜΕΓΑΛΟΥ ΟΓΚΟΥ ( >50 ml )
plasmalyte 3g10/baxter inj.so.inf inj.so.inf
baxter hellas ΕΠΕ - electrolytes with carbohydrates - ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ ΓΙΑ ΕΝΔΟΦΛΕΒΙΑ ΕΓΧΥΣΗ - inj.so.inf - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ
plasmalyte 3g5/baxter inj.so.inf inj.so.inf
baxter hellas ΕΠΕ - electrolytes with carbohydrates - ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ ΓΙΑ ΕΝΔΟΦΛΕΒΙΑ ΕΓΧΥΣΗ - inj.so.inf - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ